瞄準全球高端客群：日本京急與JTB聯手，佈局羽田機場醫療旅遊
日本鐵道商京急與旅行社JTB聯手，在東京羽田機場附近推出醫療旅遊試點計畫。此舉旨在結合日本先進醫療與觀光資源，目標於2026財年全面啟動。
日本鐵道營運商京急電鐵（Keikyu）與旅遊業龍頭JTB公司宣布攜手合作，於東京羽田機場周邊地區啟動一項醫療旅遊試點計畫，意在整合日本的兩大優勢：世界頂級的醫療保健體系與持續火熱的國際觀光市場。
根據該計畫，合作雙方將為訪日的國際旅客提供綜合性的健康檢查服務。此舉旨在利用羽田機場作為國際門戶的地理優勢，為高端旅客打造便捷且高附加價值的旅遊體驗。日本不僅以全球名列前茅的國民平均壽命聞名，其先進的醫療技術與服務品質也備受肯定，這成為發展醫療旅遊的堅實基礎。
此項合作被視為日本觀光產業升級的關鍵一步，從單純的觀光旅遊，邁向結合健康、養生的複合式高價值服務。業者看準的正是日本在全球旅遊市場中日益增長的吸引力。
據悉，該試點計畫的目標是在2026財政年度實現全面商業化營運，預期將為日本的入境旅遊市場開創新的成長曲線。
Related Articles
Railway operator Keikyu and travel agency JTB are launching a medical tourism pilot near Haneda Airport, eyeing a full launch by FY2026. We analyze the investment case, market opportunity, and risks in Japan's new high-value tourism strategy.
Top Japanese officials have issued strong warnings after the yen fell to a one-month low of 157.78, signaling potential intervention despite a recent BOJ rate hike.
As the Bank of Japan steps back, the Japanese government is targeting the nation's $7 trillion in household savings to fund its debt. We analyze the strategy, challenges, and what it means for JGB yields, the yen, and global investors.
Samsung Biologics is acquiring a U.S. drug production facility from GSK for $280 million. The deal marks a significant expansion into the North American CDMO market, aiming to secure local production capacity.